A specific stem cell program and CD112 immunological axis dysfunctions underpinning monosomy 7-associated myeloid neoplasms [0.03%]
Anair Graciela Lema Fernandez,Carlotta Nardelli,Martina Quintini et al.
Anair Graciela Lema Fernandez et al.
Monosomy 7 (-7) is occurring as isolated change or in complex karyotypes in 10-20% of myeloid neoplasms with poor prognosis. Although several genes mapping at chromosome 7 have been involved in pathogenetic mechanisms, the -7 molecular land...
Xiangyun Mao,Zhaoqing Wang,Shu Kong et al.
Xiangyun Mao et al.
First-in-class (FIC) oncology drugs-defined by their novel mechanisms of action or targeting of previously unaddressed molecular targets-have emerged as a leading force in cancer therapeutic innovation. In this Review, we delineate the glob...
SSTNIV, a syndecan-1-targeting peptide chimera, reverses immune suppression and inhibits myeloma progression [0.03%]
Oisun Jung,DeannaLee M Beauvais,Gavril L Ibaan et al.
Oisun Jung et al.
Despite therapeutic advances, multiple myeloma (MM) remains incurable, largely due to relapse and the emergence of drug resistance driven by clonal evolution and alterations in the bone marrow (BM) microenvironment that support tumor surviv...
Naresh L Selokar,Wilfried A Kues
Naresh L Selokar
Jianting Sheng,Ju Young Ahn,Li Yang et al.
Jianting Sheng et al.
Large language models (LLMs) have demonstrated impressive capabilities in summarization, reasoning, and content generation, yet their inability to directly interpret large-scale omics data has limited their utility in data-driven hypothesis...
Acute hemodynamic effects of TPN171H in pulmonary arterial hypertension: a randomized, controlled, phase 2a trial [0.03%]
TPN171H治疗肺动脉高压的急性血流动力学效应：2期随机对照试验
Yu-Ping Zhou,Lu-Hong Qiu,Wei Ma et al.
Yu-Ping Zhou et al.
Pulmonary arterial hypertension (PAH) has a poor prognosis despite available treatments. TPN171H, structurally modified from traditional Chinese medicine (Epimedium), was reported to have a high affinity for phosphodiesterase type 5 and exh...
ADAMTS4 elicits myeloid-derived immune cell recruitment and liver fibrogenesis in metabolic dysfunction-associated steatotic liver disease [0.03%]
ADAMTS4通过募集髓系衍生的免疫细胞诱导代谢功能障碍相关性肝脂肪变性疾病的肝纤维化
Jeongwoo Park,Taeeung Kim,Wan Seob Shim et al.
Jeongwoo Park et al.
A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4) has been implicated in arthritis and lung fibroblast activation; however, its role in liver homeostasis and fibrogenesis remains largely unexplored. Here, we investi...
Antagonistic pleiotropy in disease tolerance: Foxo1-Trim63 axis as double-edged sword in age-dependent sepsis [0.03%]
疾病耐受性的拮抗多效性：Foxo1-Trim63轴在年龄依赖性脓毒症中的双刃剑作用
Unbin Chae,Jin-Man Kim,Young-Ho Park
Unbin Chae
Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial [0.03%]
sintilimab（pd-1抑制剂）联合仑伐替尼作为新辅助治疗后序贯手术(silenese研究) 治疗不可切除的局部晚期肝细胞癌：一项Ⅱ期、扩展临床试验
Shichun Lu,Wenwen Zhang,Junfeng Li et al.
Shichun Lu et al.
Our previous findings demonstrated the promising antitumor activity and manageable safety of sintilimab-lenvatinib conversion therapy. The current study aimed to evaluate long-term survival outcomes in patients with unresectable hepatocellu...
Low-dose radiotherapy synergizes with PD-1 blockade to achieve durable survival in advanced NSCLC through antitumor neutrophil programming [0.03%]
低剂量放疗通过抗肿瘤中性粒细胞编程与PD-1阻断协同作用以达到晚期非小细胞肺癌的持久生存率
Laiyan Zhou,Yuanxin Liu,Zherui Xing et al.
Laiyan Zhou et al.
The optimal strategy for combining radiotherapy (RT) and immunotherapy remains under intensive investigation. Here we developed TRIDENT (Triple Radio-Immunotherapy-Driven ENhanced Therapy), a novel triple-modality regimen combining immunomo...